Rigel Shares Get Crushed
Updated from 9:56 a.m. EST
Rigel Pharmaceuticals (RIGL) was taken to the woodshed Thursday after the company said a trial of its lead product candidate, a hay fever treatment, fell short of the study's main goal.
Shares of Rigel were plunging $13.79, or 63%, to $8.13 on tremendous volume. More than 18 million shares have changed hands, compared with an average of about 273,000 for a full session during the last three months.
The South San Francisco, Calif., company said that a midstage study compared its R112, a prospective treatment for hay fever, or allergic rhinitis, and GlaxoSmithKline's (GSK) Beconase AQ nasal spray to a placebo over a seven-day period. In the trial, the treatment with R112 failed to show a statistically significant difference vs. the placebo in improving seasonal nasal allergy symptoms, the study's primary endpoint.Beconase AQ was superior to the placebo, Rigel said in a press release. The results were especially discouraging because a previous study conducted at two sites during peak pollen season found that R112 showed a statistically significant improvement in symptoms of seasonal hay fever. Rigel says the drug began working in as little as 30 minutes. Regarding the latest trial, analysts said the twice-daily dosing schedule and a greater number of test sites may have contributed to the negative results by creating too much variance in the test environment. The most recent study was conducted in 25 centers across the U.S. At least two analysts say this particular Rigel drug may have come to the end of the road, but they believe the company has other promising avenues to pursue. "We think R112 is probably now a dead program, but believe Rigel will consider advancing more potent nasal-administered Syk inhibitors into human allergy testing in the future," analyst Martin Auster of Wachovia Capital Markets wrote in a research report. Syk inhibitors target an enzyme called syk kinase and are meant to reduce chronic inflammation in patients with nasal allergies.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV